ArticleInfectious Disease Modelling2023
Modeling vaccination strategies with limited early COVID-19 vaccine access in low- and middle-income countries: A case study of Thailand.
Article in Infectious Disease Modelling, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 14 citations in OpenAlex.
- COVID-19 Vaccine Coverage and Adverse Event Among Cancer Patients During the 2021-2022 SARS-CoV-2 Outbreaks in Thailand: A Retrospective Cohort Study.Journal of community health · 2026Article
- Modeling the effectiveness of RT-PCR, RT-LAMP, and antigen testing strategies for COVID-19 control.BMC infectious diseases · 2025Article
- Seasonal and Meteorological Drivers of Hand, Foot, and Mouth Disease Outbreaks Using Data-Driven Machine Learning Models.Tropical medicine and infectious disease · 2025Article
- Learning from the COVID-19 pandemic: A systematic review of mathematical vaccine prioritization models.Infectious Disease Modelling · 2024Review
- A novel comparison framework for epidemiological strategies applied to age-based restrictions versus horizontal lockdowns.Infectious Disease Modelling · 2024Article
- Real world effectiveness of early ensitrelvir treatment in patients with SARS-CoV-2, a retrospective case series.New microbes and new infections · 2024Article
- Impact of COVID-19 Vaccination in Thailand: Averted Deaths and Severe Infections Across Age Groups.Tropical medicine and infectious disease · 2024Article
- Early treatment with fluvoxamine, bromhexine, cyproheptadine, and niclosamide to prevent clinical deterioration in patients with symptomatic COVID-19: a randomized clinical trial.EClinicalMedicine · 2024Article
- Vaccination strategies impact the probability of outbreak extinction: A case study of COVID-19 transmission.Heliyon · 2024Article
- Exploring indoor and outdoor dust as a potential tool for detection and monitoring of COVID-19 transmission.iScience · 2024Article
- Learning from the COVID-19 pandemic: a systematic review of mathematical vaccine prioritization models.medRxiv : the preprint server for health sciences · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Low- and middle-income countries faced significant challenges in accessing COVID-19 vaccines during the early stages of the pandemic. In this study, we utilized an age-structured modeling approach to examine the implications of various vaccination strategies, vaccine prioritization, and vaccine rollout speeds in Thailand, an upper-middle-income country experiencing vaccine shortages during the early stages of the pandemic. The model directly compares the effectiveness of several vaccination strategies, including the heterologous vaccination where CoronaVac (CV) vaccine was administered as the first dose, followed by ChAdOx1 nCoV-19 (AZ) vaccine as the second dose, under varying disease transmission dynamics. We found that the traditional AZ homologous vaccination was more effective than the CV homologous vaccination, regardless of disease transmission dynamics. However, combining CV and AZ vaccines via either parallel homologous or heterologous vaccinations was more effective than relying solely on AZ homologous vaccination. Additionally, prioritizing vaccination for the elderly aged 60 years and above was the most effective way to reduce mortality when community transmission is well-controlled. On the other hand, prioritizing workers aged 20-59 was most effective in lowering COVID-19 cases, irrespective of the transmission dynamics. Lastly, despite the vaccine prioritization strategy, rapid vaccine rollout speeds were crucial in reducing COVID-19 infections and deaths. These findings suggested that in low- and middle-income countries where early access to high-efficacy vaccines might be limited, obtaining any accessible vaccines as early as possible and using them in parallel with other higher-efficacy vaccines might be a better strategy than waiting for and relying solely on higher-efficacy vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.